The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche
Speakers' Bureau - Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celon Pharma; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Consulting or Advisory Role - 14ner; Abbvie; Achilles Therapeutics; Apollomics; Archer; Arrys/Kyn; AstraZeneca; BeyondSpring Pharmaceuticals; Bio-Thera; Blueprint Genetics; BMS Brazil; CBT Pharmaceuticals; Daiichi Sankyo; EMD Serono; G1 Therapeutics; Hansoh; Helsinn Healthcare; Hengrui Medicine; Inivata; Lilly; Medtronic; Regeneron; Ribon Therapeutics; Ribon Therapeutics; Roche/Genentech; Takeda
Research Funding - Takeda
Other Relationship - Abbvie; AstraZeneca; Bristol-Myers Squibb; Hansoh; Lycera; MedImmune; Merck; Pfizer; Phosplatin Therapeutics; Roche/Genentech; Seagen; Symphogen; Takeda
Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Illumina (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines; Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo; Debiopharm Group (Inst); Illumina (Inst); Incyte; Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - ESMO; European Thoracic Oncology Platform (ETOP); Journal of Thoracic Oncology
 
Tony S. K. Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Hutchison MediPharma; Sanomics Limited
Stock and Other Ownership Interests - Hutchison MediPharma; Sanomics Limited
Honoraria - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Fishawack Facilitate; Hutchison MediPharma; Ignyta; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Takeda; Vertex
Consulting or Advisory Role - ACEA Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Cirina; Clovis Oncology; geneDecode; Hutchison MediPharma; Ignyta; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Oncogenex; Pfizer; Roche/Genentech; SFJ Pharmaceuticals Group; Vertex
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Xcovery (Inst)
 
Shirish M. Gadgeel
Honoraria - AstraZeneca; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Novocure; Takeda; Xcovery
Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck
Other Relationship - AstraZeneca
 
Rafael Rosell
No Relationships to Disclose
 
Rafal Dziadziuszko
No Relationships to Disclose
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Hanmi (Inst); Janssen (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Sharp & Dohme; Pfizer; Roche; Takeda
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Turning Point Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Merck; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche/Genentech; Takeda; TP Therapeutics
Speakers' Bureau - AstraZeneca; Genentech; Takeda
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Ignyta (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Alice Tsang Shaw
Employment - Novartis Institutes for BioMedical Research
Leadership - Syros Pharmaceuticals
Stock and Other Ownership Interests - Novartis Institutes for BioMedical Research
Honoraria - Foundation medicine; Guardant Health; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Achilles Therapeutics; ARIAD; Bayer; Blueprint Medicines; Chugai Pharma; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - ARIAD (Inst); Daiichi Sankyo (Inst); Ignyta (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); TP Therapeutics (Inst)
 
Walter Bordogna
Employment - Roche
 
Vlatka Smoljanovic
Employment - Roche
Stock and Other Ownership Interests - Roche
Travel, Accommodations, Expenses - Roche
 
Magalie Hilton
Employment - Roche
Patents, Royalties, Other Intellectual Property - Roche
 
Thorsten Ruf
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Venice Rosale Archer
Employment - Roche
 
D. Ross Camidge
No Relationships to Disclose